Share：
Share this content in WeChat
X
[Chinese][PDF]79366
• Review •
The advanced imaging of IDH-1 mutation in gliomas
WANG Ru-jia  SHEN Gui-quan  GAO Bo 

DOI:10.12015/issn.1674-8034.2016.09.016.


[Abstract] Isocitrate dehydrogenase 1 (IDH-1) would act as a biomarker which plays a key role in determining the molecular subtypes of gliomas and individualized treatment and prognosis. More and more studies show that IDH-1 mutation is closely associated with gliomas. This paper will review the relationship between IDH-1 mutationand imaging genomics ingliomas, Hopefully it is useful to the early diagnosis, therapy 5 and outcome of gliomas.
[Keywords] Isocitrate Dehydrogenase；Genetic mutation；Glioma；Magnetic resonance imaging

WANG Ru-jia Department of Radiology, Yantai Yuhuangding Hospital, Yantai 264000, China; Department of Radiology, the Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China

SHEN Gui-quan Department of Radiology, the Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China

GAO Bo* Department of Radiology, Yantai Yuhuangding Hospital, Yantai 264000, China

*Correspondence to: Gao B, E-mail: gygb2004@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  The project is supported by the Natural Science Foundation of Shandong Province No. ZR2014HL084
Received  2016-03-25
Accepted  2016-05-30
DOI: 10.12015/issn.1674-8034.2016.09.016
DOI:10.12015/issn.1674-8034.2016.09.016.

[1]
Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol, 2015, 17(Suppl 4):iv1-iv62.
[2]
Elbana MG, Amer AM, Zinn PO, et al. Imaging genomics of Glioblastoma:state of the artbridge between genomics and neuroradiology. Neuroimaging Clin N Am, 2015, 25(1): 141-153.
[3]
Zinn PO, Colen RR. Imaging genomics mapping in glioblastoma. Neurosurgery, 2013, 60(suppl 1): 126-130.
[4]
Grant R, Kolb L, Moliterno J. Molecular and genetic pathways in glioma: the future of personalized therapeutics. CNS Oncol, 2014,3(2): 123-136.
[5]
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321(5897):1807-1812.
[6]
Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of gliomastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17(1): 98-110.
[7]
Albert L, Samir K, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol, 2011, 29(34): 4482-4490.
[8]
Sevin T, Daniel R, Anuj G, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012,483(7390): 479-483.
[9]
Leu S, Felten SV, Frank S, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol, 2013, 15(4): 469-479.
[10]
Cairns RA, Javeed I, Can K, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood, 2012, 119(8):1901-1903.
[11]
Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene, 2013, 32(25):3091-3100.
[12]
Flavalan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature, 2016, 529(7584):110-114.
[13]
Andronesi OC, Otto R, Elizabeth G, et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest, 2013, 123(9): 3659-3663.
[14]
Song T, Lei Y, He Z, et al. Isocitrate dehydrogense mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncology Letters, 2014, 7(6):1895-1902.
[15]
Ellingson BM, Lai A, Harris RJ, et al. Probabilistic radiographic atlas of glioblastoma phenotypes. Am J Neuroradiol, 2013, 34(3): 533-540.
[16]
Tan WL, Huang WY, Yin B, et al. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. Am J Neuroradiol, 2014, 35(5):920-927.
[17]
胡鸿博，刘鹏飞.磁共振弥散张量成像及纤维束成像对脑胶质瘤分级的诊断价值.磁共振成像, 2011, 2(2): 118-122.
[18]
Naeini Km, Pope WB, Cloughesy TF, et al. Identifing the mesenchymal moclecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol, 2013, 15(5): 626-634.
[19]
杨帆，温伟红，张剑宁.异柠檬酸脱氢酶1/2突变与胶质细胞瘤的发生.中华神经外科疾病研究杂志, 2013, 12(5): 478-480.
[20]
Pope WB. Genomics of brain tumor imaging. Neuroimaging Clin N Am, 2015, 25(1): 105-119.
[21]
Zou P, Xu HT, Chen P, et al. IDH1/IDH2 mutation define the prognosis and molecular profile of patients with glioma: a meta-analysis. PLoS One, 2013, 8(7): 1-7.
[22]
周良辅，毛颖，王任直,等.中国中枢神经系统胶质瘤诊断和治疗指南.中华医学杂志, 2016, 96(7): 485-509.
[23]
Jain R, Possion L, Narang J, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarker. Radiology, 2013, 267(1): 212-220.
[24]
程敬亮，杨涛.磁共振成像在脑胶质瘤中的应用及进展.磁共振成像, 2014, 5(Suppl): 62-67.
[25]
李宏，陆云涛，漆松涛,等.病理类型、IDH-1突变和MGMT启动子甲基化状态与间变性胶质瘤假性进展的相关性.暨南大学学报(医学版), 2013, 34(2): 154-159.
[26]
Zinn PO, Mahmood Z, Elbanan MG, et al. Imaging genetics in gliomas. Cancer J, 2015, 21(3): 225-234.
[27]
Gutaman DA, Cooper LA, Hwang SN, et al. MR imaging predictors of mocecular profile and survial:multi-institutional study of the TGCA glioblastoma data set. Radiology, 2013, 267(2): 560-569.
[28]
Colen RR, Vangel M, Wang J, et al. Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metablic dysfunction: a TCGA glioma phenotype research group project. BMC Med Genomics, 2014, 7(1): 1-27.
[29]
Colen RR, Wang J, Singh SK, et al. Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death. Radiology, 2015, 275(1): 215-227.
[30]
Nicolasjilwan M, Hu Y, Yan C, et al. Addition of MR imaging feature and genetic biomarlers strengthens glioblastoma survival prediction in TGCA patients. J Neuroradiology, 2015, 42(4): 212-221.

PREV Progresses of multimodal functional magnetic resonance imaging in assessment of brain default mode network damage in type 2 diabetes
NEXT Cardiac longitudinal relaxation time (T1) imaging technique and its clinical applications
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn